IMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study
On July 30, 2024, Imunon, Inc. (IMNN) announced positive topline results for the Phase 2 OVATION 2 Trial of IMNN-001 in patients with advanced...
IMNN: Results from OVATION 2 Study in Mid-2024
On May 13, 2024, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2024 and provided a business update. The company is on...
Biopharma Week in Review
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
No more insights